DRUGS FOR LOCAL TRANSDERMAL USE IN TREATING PATIENTS WITH DORSALGIA

The term «dorsopathy» now refers to pain syndromes in the back of of neurovisceral etiology related to degenerative spinal diseases.

The most important type of dorsopathies is the back pain, which, according to WHO experts, at the end of the XX century  became a non-communicable epidemic as it affects about 80 per cent of the population during life.

Dorsalgia (DA) is an exceptionally common skeletal pain syndrome in the population. For the treatment of patients nonsteroid antiinflammatory drugs (NSAIDs) with express pain and anti-inflammatory effects are widely used. Their indication is often associated with the risk of side effects, which are increasing in older patients with polymorbidity requiring simultaneous administration of several drugs at the same time. An alternative to systemic use of NSAIDs may in some cases be the local use of transdermal forms of drugs. Consideration is being given to the use of Deep Relief and Deep Hit in patients with DA depending on the characteristics of the clinical pattern of the disease. Research findings on the bioavailability, efficiency and tolerability of drugs are presented.

1. Sivasubramaniam V., Patel H., Ozdemir B., et al. Trends in hospital admissions and surgical procedures for degenerative lumbar spine disease in England: a 15-year time series study. BMJ Open. 2015;5:e009011. doi:10.1136/bmjopen-2015009011.

2. Vos T, Flaxman A, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2163–96.

3. Насонов Е.Л., Яхно Н.Н., Каратеев А.Е. и соавт. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016; 54(3): 247–265. (Nasonov E.L., Yahno N.N., Karateev A.E. i soavt. Obschie printsipyi lecheniya skeletno-myishechnoy boli: mezhdistsiplinarnyiy consensus. Nauchno-prakticheskaya revmatologiya. 2016; 54(3): 247–265 [In Russ])

4. Wong J., Cote P., Sutton D. et al. Clinical practice guidelines for the noninvasive management of low back pain: A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Eur J Pain. 2017; 21(2): 201–216. doi: 10.1002/ejp.931.

5. Баранцевич Е.Р., Андреев В. Возможности лечения хронической боли при пояснично-крестцовой радикулопатии. Врач. 2012; 11: 13–19. (Barancevich E.R., Andreev V. Vozmozhnosti lechenija hronicheskoj boli pri pojasnichno-krestcovoj radikulopatii. Vrach. 2012; 11: 13–19 [In Russ]).

6. Барулин А.Е., Курушина О.В., Пучков А.Е. Комплексное лечение острой неспецифической боли в нижней части спины. Неврология, нейропсихиатрия, психосоматика. 2014;6(3):38–42. DOI:10.14412/2074-2711-2014-3-38-42 (For citation: Barulin A.E., Kurushina O.V., Puchkov A.E. Combination treatment for acute non-specific low back pain. Neurology, Neuropsychiatry, Psychosomatics. 2014;6(3):38–42. [In Russ]).

7. Есин Р.Г., Есин О.Р., Ахмадеева Г.Д., Салихова Г.В. Боль в спине. Казань: Казанский полиграфкомбинат, 2010 – 272 с. (Esin R.G., Esin O.R., Ahmadeeva G.D., Salihova G.V. Bol’ v spine. Kazan’. Kazanskij poligrafkombinat. 2010– 272 s. [In Russ]).

8. Chou R., Qaseem A., Snow V. et al. Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007; 147: 478–491.

9. Roberts E., Nunes V., Buckner S. et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016; 75: 552–559. doi:10.1136/annrheumdis-2014-206914.

10. Saragiotto B., Machado G., Ferreira M. et al. Paracetamol for low back pain. Cochrane Database Syst Rev. 2016 Jun 7;(6):CD012230. doi: 10.1002/14651858.CD012230.

11. Kötter T., da Costa B., Fässler M. et al. Metamizole-Associated Adverse Events: A Systematic Review and Meta-Analysis. PLoS ONE. 201510(4): e0122918. doi:10.1371/journal.pone.0122918.

12. Yang M., Wang H.-T., Zhao M. et al. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine (Baltimore). 2015; 94; 40: P15-12576. DOI: 10.1097/MD.0000000000001592.

13. Nissen S., Yeomans N., Solomon D. et al. Cardiov ascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016; 375(26): 2519-29. doi: 10.1056/NEJMoa1611593.

14. Arfе A., Scotti L., Varas-Lorenzo C. et al. Nonsteroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016; 354: i4857. http://dx.doi.org/10.1136/bmj.i4857.

15. Moore N., Pollack C., Butkerait P. Adverse drug reactions and drug–drug interactions with overthe-counter NSAIDs. Ther Clin Risk Manag. 2015; 11: 1061–1075. doi: 10.2147/TCRM.S79135.

16. Trimble J., Light B. Effect of Penetration Enhancers on the Percutaneous Delivery of Pain Management Actives. Int J Pharm Compd. 2016; 20(3): 250–256.

17. Rother M., Conaghan P. A randomized, doubleblind, phase III trial in moderate osteoarthritis knee pain comparing topical ketoprofen gel with ketoprofen-free gel. J Rheumatol. 2013; 40(10): 1742-8. doi: 10.3899/jrheum.130192.

18. Derry S., Moore A., Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2014; 9: CD007400. doi:10.1002/14651858.CD007400.pub2.

19. Derry S., Conaghan P., Da Silva J. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016 Apr 22;4:CD007400. doi: 10.1002/14651858.CD007400.pub3.

20. Rainsford KD. Ibuprofen: from invention to an OTC therapeutic mainstay. Int J Clin Pract Suppl. 2013 Jan;(178):9-20. doi: 10.1111/ijcp.12055.

21. Patel A., Bell M., O’Connor C et al. Delivery of ibuprofen to the skin. Int J Pharm. 2013; 457(1): 9-13. doi: 10.1016/j.ijpharm.2013.09.019.

22. Al-Saidan SM. Transdermal self-permeation enhancement of ibuprofen. J Control Release. 2004; 100(2): 199–-209.

23. Gee CM, Watkinson AC, Nicolazzo JA, Finnin BC. The effect of formulation excipients on the penetration and lateral diffusion of ibuprofen on and within the stratum corneum following topical application to humans. J Pharm Sci. 2014; 103(3): 909-19. doi: 10.1002/jps.23850.

24. Brain K., Green D., Dykes P. et al. The role of menthol in skin penetration from topical formulations of ibuprofen 5% in vivo. Skin Pharmacol Physiol. 2006; 19(1): 17-21. DOI: 10.1159/000089139.

25. Hasler-Nguyen N, Fotopoulos G. Effect of rubbing on the in vitro skin permeation of diclofenacdiethylamine1,16% gel. BMC Res Notes. 2012 Jun 21;5:321. doi: 10.1186/1756-0500-5-321.

26. Saino V., Monti D., Burgalassi S. et al. Optimization of skin permeation and distribution of ibuprofen by using nanostructures (coagels) based on alkyl vitamin C derivatives. Eur J Pharm Biopharm. 2010 Nov; 76(3):443-9. doi: 10.1016/j.ejpb.2010.08.004.

27. Dostál C., Pavelka K., Lewit K. Ibuprofen in the treatment of the cervicocranial syndrome in combination with manipulative therapy. Fysiatr Revmatol Vestn. 1978; 56(5): 258-63.

28. Barkin RL. Topical Nonsteroidal Anti-Inflammatory Drugs: The Importance of Drug, Delivery, and Therapeutic Outcome. Am J Ther. 2015; 22(5): 388-407. doi: 10.1097/MJT.0b013e3182459abd.

29. Rivera JC., Hsu JR., Noel SP. et al. Locally Delivered Nonsteroidal Antiinflammatory Drug: A Potential Option for Heterotopic Ossification Prevention. Clin Transl Sci. 2015; 8(5): 591-3. doi: 10.1111/cts.12300.

30. Malanga G., Yan N., Stark J. Mechanisms and efficacy of heat and cold therapies for musculoskeletal injury. Postgrad Med. 2015; 127(1): 57-65. DOI: 10.1080/00325481.2015.992719.

31. Collins A., Notarianni L., Ring E., Seed M. Some observations on the pharmacology of ‘deepheat’, a topical rubifacient. Ann Rheum Dis. 1984; 43(3): 411-5.

32. McIntosh G., Hall H. Low back pain (acute). Clinical Evidence 2008; 10: 1102-1127.

33. Mason L, Moore A, Edwards J, Derry S. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord. 2004; 5: 28. doi: 10.1186/1471-2474-5-28.

34. McCarberg B., D’Arcy Y. Options in topical therapies in the management of patients with acute pain. Postgrad Med. 2013; 125(4 Suppl 1): 19-24. DOI: 10.1080/00325481.2013.1110567011.

35. Stanos SP., Galluzzi KE. Topical therapies in the management of chronic pain. Postgrad Med. 2013; 125(4 Suppl 1): 25-33. DOI: 10.1080/00325481.2013.1110567111.

36. Böhme K., Heckes B., Thomitzek K. Application of a seven-day buprenorphine transdermal patch in multimorbid patients on longterm ibuprofen or diclofenac. MMW Fortschr Med. 2011; 152 Suppl 4: 125-32.